Biocross is also developing screening technologies for populations with an elevated risk of late-onset AD.
The e4Risk® is a non-genetic, cost-effective, and highly reliable method to detect the presence of the ApoE4 protein in human blood plasma using high-throughput chemistry analyzers.
This is achieved using a turbidimetry-based assay with excellent performance in the context of the hospital/clinical settings (100% sensitivity and 99% specificity).
CE Marking. The process of obtaining the FDA approval for the e4Risk® is currently ongoing.
*Test based on patent nº EP15382537.7: “Methods for apolipoprotein detection”
The AD Dementia test is a multiparametric test that combines the detection and quantification of up to 9 metabolites or proteins in a plasma sample. Input of these measurements into an algorithm provides an accurate diagnosis and classifies the patient as either AD (Alzheimer´s disease), FTD (frontotemporal dementia) or healthy.
The AD Dementia test is currently in the IVD development phase, and is expected to be available as a RUO kit by 3Q of 2020.
The Degenerative Dementia (DD) test is based on the detection and quantification of up to 7 biomarkers in the blood that are specifically altered in patients affected by neurodegeneration due to FTD or AD.
The DD test is rapid and cost-effective and may be used as a screening tool to detect early-stage neurodegeneration.
The DD test is currently in the IVD development phase and is expected to be available as a RUO kit by 3Q of 2021.
If you have any questions or comments, we will be pleased to attend you
If you have any questions or comments,
we will be pleased to attend you